NVO
Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 109.97$. Average daily volumn in 3 months 1.48M. Market cap 254.03B
Stock symbol : NVO. Exchange : NYSE. Currency : USD Lastest price : 112.12$. Total volume : 1.44M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Novo Nordisk A/S (NVO)
Last Price
112.12$Change
3.69Volume
1.44M
| Previous Close | 108.43 |
| Open | 111.81 |
| Day Range | 110.58-112.18 |
| Bid | 111.88 x 800 |
| Ask | 112.50 x 800 |
| Volume | 1.44M |
| Average Volume | 1.48M |
| Market Cap | 254.03B |
| Beta | 0.24 |
| 52 Week Range | 82.82-122.16 |
| Trailing P/E | 36.95 |
| Foward P/E | 28.38 |
| Dividend (Yield %) | 1.49% |
| Ex-Dividend Date | 2022-03-25 |
Financial Details
Organization
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormon... e replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Market Cap:
254.03BRevenue:
140.8BTotal Assets:
194.51BTotal Cash:
10.72B
News about "Novo Nordisk A/S"
Private Trust Co. NA Has $336,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)
Source from : Defense World - 1 days ago
Private Trust Co. NA raised its position in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 34.6% in the first quarter, according to its most recent filing with the SEC. The firm owned 3,022 ...See details»
Novo Nordisk A/S – Share repurchase programme
Source from : Yahoo - 5 days ago
On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the ...See details»
First Affirmative Financial Network Grows Holdings in Novo Nordisk A/S (NYSE:NVO)
Source from : Defense World - 3 days ago
First Affirmative Financial Network lifted its holdings in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 8.5% during the first quarter, according to its most recent 13F filing with the Securities and ...See details»
Novo Nordisk A/S (NYSE:NVO) Short Interest Down 29.0% in May
Source from : ETF Daily News - 11 days ago
Novo Nordisk A/S (NYSE:NVO – Get Rating) saw a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 1,710,000 shares, a drop of 29.0% from ...See details»
Novo Nordisk A/S (NYSE:NVO) Upgraded at Guggenheim
Source from : ETF Daily News - 25 days ago
Novo Nordisk A/S (NYSE:NVO – Get Rating) was upgraded by equities researchers at Guggenheim from a “neutral” rating to a “buy” rating in a research report issued on Tuesday, The Fly reports.See details»
Novo Nordisk A/S:
Source from : Yahoo News - 18 days ago
Bagsværd, Denmark, 7 June 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5% of the ...See details»
Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH
Source from : YAHOO!Finance - 3 days ago
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, today announced a partnership to advance early diagnosis of ...See details»
Novo Nordisk A/S: Our New Capsule System Tackles Biopharma ESG Risk Tied to U.S. Drug Pricing and Cost-Effectiveness
Source from : Yahoo Finance - 13 days ago
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and ...See details»
Will investors benefit from quality and momentum at Novo Nordisk A/S?
Source from : Yahoo Finance - 3 days ago
The Novo Nordisk A/S (CPH:NOVO B) share price is currently trading at DKK761.9. But to predict what the price will look like in the next 12 months and beyond, ...See details»
Novo Nordisk A/S ADR - Stock Dividends 0TDD
Source from : Morningstar%2c Inc. - 12 days ago
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...See details»
3 Reasons Why Novo Nordisk (NVO) Is a Great Growth Stock
Source from : Nasdaq - 8 days ago
While the historical EPS growth rate for Novo Nordisk is 7.6%, investors should actually focus on the projected growth. The company's EPS is expected to grow 6.7% this year, crushing the industry ...See details»
Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
Source from : Yahoo - 13 days ago
“Sogroya ® shows Novo Nordisk’s commitment to the rare endocrine community and our continued vision to deliver innovative therapeutic solutions for all patient needs.” About the REAL4 trial ...See details»
Is Novo Nordisk (NVO) a Smart Long-Term Investment?
Source from : Yahoo Finance - 10 days ago
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended March 31, 2022, Baron ...See details»
Johnson & Johnson Or Novo Nordisk: Which Is The Best Big Pharma Near Cap-Gainer
Source from : Seeking Alpha - 9 days ago
In this article, I discuss about Johnson & Johnson and Novo Nordisk. Read more to know among JNJ and NVO stocks, which one is attractive.See details»